DB15698ExperimentalVaccines
BNT162c2 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech. BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid... BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).
What you can answer from here — as of April 02, 2025
Which companies are running trials of BNT162c2 SARS-CoV-2 Vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account